Recently, the Congress Center Basel in Switzerland welcomed the much-anticipated BOS Basel 2024 conference, an international professional exhibition focusing on the outsourcing of pharmaceutical research and development. As a global provider of pharmaceutical outsourcing services, Laviana Pharma was once again honored to participate in this grand event, showcasing its core competitiveness and service advantages in the field of pharmaceutical outsourcing.
According to reports, the BOSBasel2024 exhibition is dedicated to CMC outsourcing services for small molecules and biologics in the development phase, with a particular focus on novel therapeutic entities. The exhibition brought together multinational pharmaceutical companies, specialized pharmaceutical enterprises, small and medium-sized biotechnology firms, CRO/CMOs, and consulting firms from various organizations. High-quality presentations and discussions covered not only outsourcing business processes and technical operations but also in-depth case studies, providing an efficient platform for industry professionals to exchange ideas.
At this exhibition, Laviana Pharma showcased its research and development projects, technological innovations, as well as its market strategy in the pharmaceutical outsourcing sector. Our business team engaged in in-depth conversations with numerous pharmaceutical companies worldwide, thoroughly understanding their requirements, sharing industry insights, exploring opportunities in the pharmaceutical technology sector, and further strengthening partnerships.
Laviana Pharma consistently prioritizes customer needs in establishing and executing a rigorous quality assurance system, ensuring our services meet global regulatory standards, and providing a reliable, swift, and efficient one-stop CDMO service to clients worldwide.
In the future, Laviana Pharma will continue to participate in international events, strengthen pharmaceutical innovation and production capabilities, while deepening global cooperation. Laviana Pharma is dedicated to Become a flagship CDMO enterprise , striving to enhance production quality and service levels in order to contribute to the high-quality development of the pharmaceutical industry and accelerate global pharmaceutical innovation.